Sirofel™ veterinary information.
Sirolimus delayed-release tablets for veterinarian-directed management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). The sections below summarise indication, patient eligibility, contraindications, the suggested workflow, dosing principles, and safety information.
Subclinical HCM as the target population.
Sirofel™ tablet
strengths.
Sirofel™ is positioned for veterinarian-directed use in otherwise healthy cats with confirmed subclinical HCM. Subclinical HCM is generally defined as echocardiographic evidence of left ventricular hypertrophy (LV wall thickness ≥6 mm at end diastole by 2D or M-mode assessment), in the absence of congestive heart failure, arterial thromboembolism, severe LV outflow tract obstruction, systemic hypertension, or arrhythmias requiring specific anti-arrhythmic therapy.
Three tablet strengths and standardised pack formats support veterinary dosing flexibility across the typical feline weight range. Tablets are delayed-release (enteric film-coated) and intended to be administered whole.
Sirofel™ tablet strengths.
0.4 mg tablets
12-tablet standard pack
Sirolimus delayed-release tablets. Administered whole — do not split or crush.
1.2 mg tablets
12-tablet standard pack
Sirolimus delayed-release tablets. Administered whole — do not split or crush.
2.4 mg tablets
12-tablet standard pack
Sirolimus delayed-release tablets. Administered whole — do not split or crush.